Latest Feature Articles
EU regulatory momentum could catalyse clinical trial innovation
Regulatory Affairs, Research and Development | AI, Corporate, EU regulation, Hospital Management, Pharmacy, Veeva SystemsDr Werner Engelbrecht at Veeva Systems discusses how compliance can be turned into a competitive advantage with connected platforms and …
Five Facts about mental health
Medical Communications, Medical Education, Research and Development | European Commission, Pharmacy, Psychiatry, mental health, mental health condition32% of people suffer from at least one mental health issue, with daily struggles like financial and job insecurity being …
Mind the gap: men’s health and the need for progress
Advocacy Development, Medical Communications, Medical Education, Research and Development | Androlabs, Men's Health Strategy, Men's mental health, Movember Foundation, Pharmacy, Psychiatry, mental healthFrom prostate cancer to hormonal health, many areas of men’s health require more attention. As male life expectancy and healthy …
Rare disease clinical trials: the urgent need for patients to be heard
| Alexion, Pharmafocus, Rare Diseases, clinical trials, featureAhead of Clinical Trials Day, Soraya Bekkali, from Alexion, AstraZeneca Rare Disease, highlights the urgent need to elevate patients’ voices …
Sustainability in pharma
| Pharmacy, Pharmafocus, feature, sustainabilityBetsy Goodfellow from Pharmafocus considers the need for sustainable practices in the pharma industry and assesses various sustainable advances that have already …
An overview of women’s health in 2024
| Reproductive health, abortion, fertility, reproductive health, women's healthBetsy Goodfellow from Pharmafocus considers the current landscape of women’s health, covering recent debates and ongoing issues within the reproductive health sphere …
Measles: the UK’s next epidemic?
| MMR, measles, vaccinesRecently, the UK has seen a rapid increase in the number of cases of measles, along with a drop in …
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
Business Services |PARIS, FRANCE, STRICTLY EMBARGOED until 11.00pm CET, 13 February 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, …
Veeva la Vida: A Roundup of the R&D and Quality Summit 2022
|Timeline On the 8 June, we had the pleasure of joining Veeva at their 2022 Life Sciences Summit in Zurich, …
Appy Days: How the smartphone app is revolutionising mental healthcare
|Over the last decade, our individual awareness and understanding of mental health has risen to unprecedented levels. Despite its pitfalls, …
Injecting real-world data into every day clinical trials – RWE and RWD
|The past two years have seen unprecedented pressure on healthcare systems, its workers, and clinical research as a whole. COVID-19 …
Preparation Preconditions: What measures are needed to combat another pandemic?
|Could we have foreseen the damage caused by the COVID-19 pandemic? This is a central question that has plagued biopharma …
Shaping the new frontiers of women’s health
|March 8 was International Women’s Day and provided a perfect opportunity for Pharmafocus to dive deep into women’s health. Lina …
Technology on trial – the latest cogs in the clinical machine
|From the integration of social media to everyday life, to the seeping of AI into our daily lives, the past …
Access denied: Is Brexit spelling bedlam for UK clinical trials?
|Since Article 50 was triggered on the 29 March 2017, the UK’s pharmaceutical industry collectively held its breath, bracing itself …
